PharVision Advisers’s AT&T T Stock Holding History

PharVision Advisers’s Portfolio T Stock Details T Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,610	Closed	-$388K	–	581
2025 Q4	$388K	Buy	+15,610	New	+$395K	0.2%	141

Other funds holding T

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newport Trust Company Washington, District of Columbia $40.7B AUM 24.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's T Position: Q1 2026 in Review

PharVision Advisers sold out of AT&T (T) in Q1 2026, closing a stake of 15,610 shares — an estimated $388K sold.

PharVision Advisers first reported a position in T in Q4 2025 and held it in 1 quarter. The position peaked at $388K in Q4 2025. 2,964 funds tracked by Wall St. Rank hold T as of Q1 2026.

PharVision Advisers reported no remaining AT&T position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 15,610 AT&T shares in Q1 2026, an estimated $388K.
PharVision Advisers first reported a position in AT&T in Q4 2025 and held it in 1 quarter.
PharVision Advisers's AT&T position peaked at $388K in Q4 2025.
2,964 funds tracked by Wall St. Rank held AT&T as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.